Journal of cancer science and clinical therapeutics最新文献_第10页

Assessment of circulating VEGF as a predictive biomarker of peritoneal carcinomatosis in gastric cancer 评估循环VEGF作为胃癌腹膜癌病变的预测性生物标志物

Journal of cancer science and clinical therapeutics Pub Date : 2020-06-29 DOI: 10.36879/jcst.20.000121

{"title":"Assessment of circulating VEGF as a predictive biomarker of peritoneal carcinomatosis in gastric cancer","authors":"","doi":"10.36879/jcst.20.000121","DOIUrl":"https://doi.org/10.36879/jcst.20.000121","url":null,"abstract":"Introduction: Early diagnosis of peritoneal carcinomatosis is difficult in patients with gastric cancer who are at high risk of developing\u0000peritoneal metastases. The measurement of serum Vascular Endothelial Growth Factor (VEGF) has proven to be a useful prognostic\u0000factor in gastric cancer, but it also could be a predictive factor for peritoneal metastases since the VEGF signalling pathway is directly\u0000involved in the development of peritoneal metastases.\u0000Methods: This is a retrospective study from 2005 to 2017. We reviewed the peritoneal recurrence pattern of a cohort of 59 gastric\u0000cancer patients in whom serum VEGF was measured before surgery and after completion of adjuvant treatment\u0000Results: Preoperative serum VEGF (pre-VEGF) level was identified as an independent prognostic factor for developing peritoneal\u0000metastases. The optimal cut-off value of pre-VEGF levels was 507 pg/mL, which presented a sensitivity of 66 % and a specificity of\u000078% to predict the development of peritoneal metastases. Patients with high pre-VEGF levels (>507 pg/mL) were at greater risk of\u0000developing peritoneal metastases than patients with low pre-VEGF levels (<507 pg/mL) (p=0.023).\u0000Conclusions: VEGF plays a crucial role in the development of peritoneal metastases, and serum VEGF meets the requirements of a\u0000potential predictive marker for peritoneal carcinomatosis. Therefore, the measurement of serum VEGF levels could be useful during\u0000the follow-up of patients with advanced gastric cancer.","PeriodicalId":73634,"journal":{"name":"Journal of cancer science and clinical therapeutics","volume":"91 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2020-06-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"84402989","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Prognosis analysis of patients with resectable T4 colorectal cancer 可切除T4结直肠癌患者的预后分析

Journal of cancer science and clinical therapeutics Pub Date : 2020-06-26 DOI: 10.21203/rs.3.rs-37853/v1

Wei Chen, Xiao-ping Tan, Junwen Ye, Yan Zhang, Jing-lin Liang, Mei Huang

{"title":"Prognosis analysis of patients with resectable T4 colorectal cancer","authors":"Wei Chen, Xiao-ping Tan, Junwen Ye, Yan Zhang, Jing-lin Liang, Mei Huang","doi":"10.21203/rs.3.rs-37853/v1","DOIUrl":"https://doi.org/10.21203/rs.3.rs-37853/v1","url":null,"abstract":"\u0000 Objective: To observe the factors related to survival and prognosis of patients with resectable stage T4 colorectal cancer. Methods : 148 patients with resectable stage T4 colorectal cancer who underwent surgery in the first Affiliated Hospital of Sun Yat-sen University between August, 1994 and December, 2005 were retrospectively analyzed. Univariate and multivariate analyses of associations between clinicopathological variables and survival were analyzed using the Cox regression model. Results: At the end of December of 2010 or death, the 5-year and 10 years OS rates were 49.0% and 32.2% respectively, the median OS was 25 months. The disease free survival rates (DFS) at 5 and 10 years were 44.2% and 30.3% respectively. In univariate analysis, patients with postoperative pathology lymph node metastasis was associated with the prognosis of patients with OS (all P< 0.01), postoperative adjuvant therapy failed to improve OS and DFS (P>0.05). Postoperative pathology lymph node metastasis was associated with DFS too (all P< 0.01). In multivariate analysis, postoperative pathology lymph node metastasis was independent factor affected OS and DFS in colorectal cancer patients. Conclusion: Postoperative prognosis of T4 colorectal cancer patients is poor, postoperative pathology lymph node positive was an independent factor affect OS and DFS.","PeriodicalId":73634,"journal":{"name":"Journal of cancer science and clinical therapeutics","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2020-06-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"42894791","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

PD-L1 regulation in colorectal cancer and role of DNA damage induced by chemotherapies PD-L1在结直肠癌中的调控及化疗诱导DNA损伤的作用

Journal of cancer science and clinical therapeutics Pub Date : 2020-05-29 DOI: 10.36879/jcst.20.000120

{"title":"PD-L1 regulation in colorectal cancer and role of DNA damage induced by chemotherapies","authors":"","doi":"10.36879/jcst.20.000120","DOIUrl":"https://doi.org/10.36879/jcst.20.000120","url":null,"abstract":"For patients with metastatic colorectal cancer (CRC), first-line therapy is based on chemotherapeutic agents, such as oxaliplatin,\u00005-fluorouracil and irinotecan. These drugs increase the overall survival, but resistance to therapy appears in almost 90% of patients,\u0000and the 5-year survival rate for patients with metastatic CRC is only about 12%.\u0000During the last few years, immune checkpoints blockade therapies have been developed and show good response in different cancers,\u0000including CRC with microsatellite instability (MSI). In this CRC subtype, the response rate to anti-PD-(L)1 antibodies is high thanks to\u0000the presence of neoantigens and tumor-infiltrating lymphocytes that are associated with the anti-tumor immune response. Nivolumab\u0000and pembrolizumab, two anti-PD-1 antibodies, have been approved for CRC MSI treatment. Moreover, it has been shown that the\u0000combination of chemotherapy and anti-PD-(L)1 molecules may convert cold tumors into hot tumors in which the immune system and\u0000T-cell infiltration are activated. In addition, recent studies found that DNA damage induces PD-L1 expression. ATM, ATR, DNA-PKcs\u0000and Chk1 are key sensors of the DNA damage response that regulate PD-L1 expression.\u0000This review summarizes the current knowledge on PD-L1 regulation at the genetic, epigenetic, transcriptional and translational\u0000levels. It also describes PD-L1 activation in response to chemotherapy and DNA damage. Then, it summarizes the current clinical\u0000trials that assess anti-PD-(L)1 therapies in combination with kinase inhibitors or chemotherapeutic agents in CRC.","PeriodicalId":73634,"journal":{"name":"Journal of cancer science and clinical therapeutics","volume":"24 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2020-05-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"84042792","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

A review on moderated-t methods for differential expression detection 差异表达检测的调节-t方法综述

Journal of cancer science and clinical therapeutics Pub Date : 2020-02-28 DOI: 10.36879/jcst.20.000119

引用次数: 0

Capillary leak syndrome (CLS) from rituximab therapy of lymphoma 利妥昔单抗治疗淋巴瘤引起的毛细血管渗漏综合征

Journal of cancer science and clinical therapeutics Pub Date : 2020-02-27 DOI: 10.36879/jcst.20.000118

引用次数: 0

In Australia mortality from melanoma is decreasing but increasing for nonmelanoma skin cancer 在澳大利亚，黑色素瘤的死亡率正在下降，但非黑色素瘤皮肤癌的死亡率却在上升

Journal of cancer science and clinical therapeutics Pub Date : 2020-02-24 DOI: 10.36879/jcst.20.000117

引用次数: 0

Summary and case observation of tumour treating fields therapy for glioblastoma 恶性胶质瘤的肿瘤野治疗总结及病例观察

Journal of cancer science and clinical therapeutics Pub Date : 2020-02-17 DOI: 10.36879/jcst.20.000116

L. Zeng, Y-H Liu, X. Wang, Y. Luo, L. Xie, P. Li, L. Bai

引用次数: 0

Bladder-sparing trimodal therapy versus radical cystectomy for muscleinvasive bladder cancer: A systematic review and meta-analysis of comparative studies 肌肉浸润性膀胱癌保留膀胱三模式治疗与根治性膀胱切除术:比较研究的系统回顾和荟萃分析

Journal of cancer science and clinical therapeutics Pub Date : 2020-01-27 DOI: 10.36879/jcst.20.000115

{"title":"Bladder-sparing trimodal therapy versus radical cystectomy for muscleinvasive bladder cancer: A systematic review and meta-analysis of comparative studies","authors":"","doi":"10.36879/jcst.20.000115","DOIUrl":"https://doi.org/10.36879/jcst.20.000115","url":null,"abstract":"Objective: To compare oncologic outcomes between patients with muscle-invasive bladder cancer who were treated with radical cystectomy (RC) or\u0000trimodal therapy (TMT).\u0000Materials and Methods: The primary sources were the PubMed, Embase, and Cochrane Library electronic databases. Studies published between\u0000June 1990 and July 2017 that evaluated combination bladder-sparing surgery for a bladder tumour with radiotherapy (RT) and chemotherapy\u0000compared with RC surgery alone for MIBC were included. Published data were extracted and used to calculate the 5-year overall survival rates. The\u0000secondary efficacy endpoints were disease-free survival and local and distant recurrence.\u0000Results: Nine studies incorporating 15,160 cases were included in the final analysis. Pooled data from 8 studies that assessed overall survival rates\u0000for 15,089 patients showed no significant differences in this metric between the TMT and RC groups (HR: 1.27; 95% CI, 0.98-1.63; P=0.066). No\u0000significant differences were found between TMT and RC in the subgroup analyses according to the lymph node stage (Nx), age and physiclal status\u0000(PS) stage, but differences were found for patients with node-negative disease (HR: 1.36; 95% CI, 1.02-1.81; P=0.036). Disease-free survival and\u0000local and distant recurrence did not differ significantly between the techniques.\u0000Conclusion: RC seems to be suitable for node-negative disease patients. TMT yielded survival outcomes similar to those of patients who underwent\u0000RC. Given the inherent limitations of the included studies, future well-designed RCTs are needed to confirm and update the findings of this analysis.","PeriodicalId":73634,"journal":{"name":"Journal of cancer science and clinical therapeutics","volume":"497 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2020-01-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"78261194","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Trajectories of hospitalization in three groups of patients with incurable gastric cancer identified by hierarchical clustering: A retrospecitve analysis 通过分层聚类确定的三组无法治愈的胃癌患者的住院轨迹:回顾性分析

Journal of cancer science and clinical therapeutics Pub Date : 2020-01-15 DOI: 10.21203/rs.2.20848/v1

Y. Murakawa, M. Sakayori, Kazunori Otsuka

{"title":"Trajectories of hospitalization in three groups of patients with incurable gastric cancer identified by hierarchical clustering: A retrospecitve analysis","authors":"Y. Murakawa, M. Sakayori, Kazunori Otsuka","doi":"10.21203/rs.2.20848/v1","DOIUrl":"https://doi.org/10.21203/rs.2.20848/v1","url":null,"abstract":"Purpose: The therapeutic goal for advanced solid malignancies is not to achieve cure but to prolong survival and maintain quality of life (QOL). To date, no study has reported the trajectory of the QOL throughout the clinical course of a patient with advanced malignancy. As hospitalization is considered a predictor of QOL, we retrospectively analyzed the trajectory of hospitalization in patients with incurable gastric cancer throughout the clinical course. Methods: The data of 85 patients with incurable gastric cancer were collected, including age, sex, Eastern Cooperative Oncology Group (ECOG) Performance Status (PS), treatment, histology, sites of metastases at first consultation, planned and unplanned hospitalization throughout the clinical course , and overall survival (OS). We ranked the patients by OS and hospitalization using a hierarchical clustering analysis. Results: Three clusters were identified corresponding to short, intermediate, and long OS/hospitalization (Clusters 1, 2, and 3, respectively). Patients in Cluster 3 were more likely to have an ECOG PS of 0–2 and receive palliative chemotherapy than the other clusters. No other differences in histology, age, sex, and or extra-peritoneal metastasis sites were observed between the three groups. In Cluster 3, planned hospitalization accumulated gradually during the early clinical phase, while unplanned hospitalization accumulated rapidly in later phases. Conclusions: No specific characteristics were associated with short, intermediate, and long OS/hospitalization. Patients in the long OS/hospitalization group exhibited a rapid accumulation of unplanned hospitalization during the latter clinical course. Further research is needed to identify specific predictors of and measures to avoid a long OS/hospitalization.","PeriodicalId":73634,"journal":{"name":"Journal of cancer science and clinical therapeutics","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2020-01-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"45565932","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Reversible Posterior Leukoencephalopathy Syndrome in Patients Undergoing Chemotherapy for Solid Tumors. A Case Report and Review of the Literature 实体瘤化疗患者的可逆性后脑白质病综合征。一例病例报告及文献回顾

Journal of cancer science and clinical therapeutics Pub Date : 2020-01-01 DOI: 10.26502/jcsct.5079065

Konstantinos Tsapakidis, Vasilis Papadopoulos, T. Nikolaos, P. Michailidis, Chrysoula Doxani, K. Kamposioras

{"title":"Reversible Posterior Leukoencephalopathy Syndrome in Patients Undergoing Chemotherapy for Solid Tumors. A Case Report and Review of the Literature","authors":"Konstantinos Tsapakidis, Vasilis Papadopoulos, T. Nikolaos, P. Michailidis, Chrysoula Doxani, K. Kamposioras","doi":"10.26502/jcsct.5079065","DOIUrl":"https://doi.org/10.26502/jcsct.5079065","url":null,"abstract":"Introduction: Reversible posterior leukoencephalopathy syndrome (RPLS) is a clinical entity of subtle onset of headaches, seizures, impaired vision and usually acute hypertension associated with characteristic neuroimaging findings of subcortical oedema affecting the posterior cerebral circulation. In the last two decades the causative relationship of cytotoxic and targeted antineoplastic agents with RPLS is increasingly recognized among cancer patients. Material and Methods: Herein we present a case of advanced gastric cancer that developed RPLS after treatment with the combination of chemotherapy and Trastuzumab. A comprehensive review of the English literature and the association of cytotoxic agents used in the treatment of solid tumors, with RPLS is analyzed. Results: 65 cases, median age 54.2 years, mainly female (83%) developed RPLS after chemotherapy-based treatment. Colorectal and lung cancer was the most frequent diagnosis, while platinum and gemcitabine based treatment was commonly related with the syndrome. Hypertension, seizures, headache and visual disturbance were the usual presenting symptoms. In the majority of the cases symptoms improved partially or completely in average in average 6.5 days after conservative management. Complete radiologic resolution of the symptoms was observed in 4.2 weeks in 57,5% of the cases and partial improvement in 2.6 weeks (42,5% of the cases). Conclusions: Combination or single-agent chemotherapy as well as novel anticancer drugs are associated with RPLS. Clinicians need to have a high index of suspicion and the combination of the clinical picture with the characteristic neuroimaging findings can help in the prompt diagnosis. RPLS can be reversible with appropriate supportive treatment and discontinuation of the causative factors.","PeriodicalId":73634,"journal":{"name":"Journal of cancer science and clinical therapeutics","volume":"1 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2020-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"69367973","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0